Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.43 |
| ▸ | ITGAV | P06756 | 4/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202520 | 0.92 | ITGB3 (0.37) | ITGB3ITGAVKDM4EALDH1A1GAA | |
| SCHEMBL6493907 | 0.91 | ITGB3 (0.42) | ITGB3ITGAVITGA2BTYRITGB1 | |
| SCHEMBL5204549 | 0.84 | ITGB3 (0.37) | ITGB3ITGAVITGA2BTYRALDH1A1 | |
| SCHEMBL6502342 | 0.80 | ITGB3 (0.36) | ITGB3ITGAVITGA2BITGB1ITGA4 | |
| SCHEMBL6495736 | 0.72 | ITGB3 (0.44) | ITGB3ITGAVITGA2BTYR | |
| SCHEMBL3048690 | 0.66 | ITGB3 (0.38) | ITGB3ITGAVITGA2B | |
| SCHEMBL7167643 | 0.66 | ITGB3 (0.42) | ITGB3ITGAVITGA2BGAA | |
| SCHEMBL4852776 | 0.66 | ITGB3 (0.43) | ITGB3ITGAVITGA2BGAA | |
| SCHEMBL4680620 | 0.66 | ITGB3 (0.43) | ITGB3ITGAVITGA2BGAA | |
| SCHEMBL4853017 | 0.66 | ITGB3 (0.43) | ITGB3ITGAVITGA2BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867333-B2 | EPOTHILONE SYNTHESIS BUILDING BLOCKS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND METHODS FOR THE PRODUCTION OF EPOTHILONES B, D AND EPOTHILONE DERIVATIVES | MORPHOCHEM AG (DE) | 2005-03-15 | — | — | US | disclosed |
| US-6849646-B1 | Chromenone and chromanone derivatives as integrin inhibitors | MERCK PATENT GMBH (DE) | 2005-02-01 | — | — | US | disclosed |
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | R & D BIOPHARMACEUTICALS GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | COASY, ACOX1, FDFT1 | ITGB3 3138/4885ITGAV 3448/4885ITGA2B 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.